Study of Tamoxifen and Raloxifene
The Study of Tamoxifen and Raloxifene (STAR) is a clinical trial designed determine how the drug raloxifene compares with the drug tamoxifen in reducing the incidence of breast cancer in women who are at increased risk of the disease.[1]
Research
One of the largest breast cancer prevention studies ever,[2] it included 22,000 women in 400 medical centers in the United States and Canada.[3][4][5]
The study concluded that raloxifene caused fewer side-effects and less endometrial cancer than tamoxifen.[6][7] Raloxifene was found to be more effective at preventing noninvasive breast cancer but less effective at preventing invasive breast cancer.[8]
References
- ^ "Study of Tamoxifen and Raloxifene (STAR)". Weill Cornell Medical College.
- ^ "Osteoporosis drug equals tamoxifen in preventing breast cancer", Pittsburgh Post-Gazette, April 18, 2006
- ^ "Drug Slashes Breast Cancer Risk, Study Shows", New York Times, June 16, 1999
- ^ Wickerham L. "What is the Study of Tamoxifen and Raloxifene Breast Cancer Prevention Trial?". ABC News.
- ^ "Study of Tamoxifen and Raloxifene (STAR)". Columbia St. Mary's.
- ^ "Teleconference: Study of Tamoxifen and Raloxifene (STAR) P-2". American Association for Cancer Research.
- ^ "Raloxifene or tamoxifen: Which is the right drug for you?", USA Today, April 17, 2006
- ^ "Raloxifene, Tamoxifen Both Guard Against Breast Cancer", Business Week, April 19, 2010